骨髓增生异常综合征去甲基化耐药治疗进展  

Progress on Treatment of Myelodysplastic Syndrome after Demethylation Drugs Resistance

作　　者：杨彩凤 马天泽[1] YANG Caifeng;MA Tianze(Affiliated Hospital of Yanbian University,Yanji 133000,China;不详)

机构地区：[1]延边大学附属医院,吉林延吉133000

出　　处：《中国医学创新》2022年第8期183-188,共6页Medical Innovation of China

摘　　要：表观遗传学改变,尤其是DNA甲基化的异常是导致骨髓增生异常综合征(myelodysplastic syndromes,MDS)疾病发生和发展的重要因素之一。目前去甲基化药物(hypomethylating agents,HMA)现已成为治疗较高危组MDS的一线用药。然而部分患者可能会出现HMA耐药,虽然耐药的机制尚不完全清楚,但是针对HMA耐药后的新型药物已经在MDS患者中显示出一定的疗效,本文将对新型药物的应用及进展进行综述。Epigenetic changes,especially abnormal DNA methylation,are one of the important factors leading to the occurrence and development of myelodysplastic syndromes (MDS).At present,hypomethylating agents (HMA) have become the first-line drugs for the treatment of MDS in the higher-risk group.However,some patients may develop HMA resistance.Although the mechanism of resistance is not fully understood,new drugs targeting HMA resistance have shown a certain effect in MDS patients,this review will review the application and progress of new drugs.

关 键 词：骨髓增生异常综合征 去甲基化耐药 新型药物 

分 类 号：R551.3[医药卫生—血液循环系统疾病]